




RealRate

PHARMACEUTICAL 2017

NovaBay Pharmaceuticals Inc.
Rank 205 of 292





RealRate

PHARMACEUTICAL 2017

NovaBay Pharmaceuticals Inc. Rank 205 of 292



The relative strengths and weaknesses of NovaBay Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NovaBay Pharmaceuticals Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 63% points. The greatest weakness of NovaBay Pharmaceuticals Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 94% points.

The company's Economic Capital Ratio, given in the ranking table, is -7.9%, being 11% points below the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	14,471
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,323
Liabilities, Non-Current	198
Other Assets	539
Other Compr. Net Income	0
Other Expenses	14,275
Other Liabilities	3,759
Other Net Income	-2,167
Other Revenues	11,897
Property and Equipment	371
Research and Development	1,371
Selling, General and Administrative Expense	7,235

Output Variable	Value in 1000 USD
Assets	15,381
Liabilities	8,280
Expenses	22,881
Revenues	11,897
Stockholders Equity	7,101
Net Income	-13,151
Comprehensive Net Income	-13,151
Economic Capital Ratio	-7.9%